Demographical and Clinical Profile of Patients on Dual Antıplatelet Therapy and Mean Precise-DAPT and DAPT Scores in Turkey

NCT03601013 | Completed

• 1 other identifier: DAPT-TR
• Study Type: observational
• Target: 963
• Locations: 1 country
• Sites: 1

Brief Summary

Coronary Artery Disease (CAD) is leading cause of death worldwide. Most of them underwent coronary angiography and they have to use dual anti-platelet therapy. As mentioned novel guidelines for CAD, the estimated number of patients requiring dual anti-platelet therapy has increased over time, and DAPT time is controversial. Acting on the behalf of 2017 ESC focused update on dual anti-platelet therapy in coronary artery disease developed in collaboration with EACTS guideline, this study is amid to determine PRECISE-DAPT score which predicts out of hospital bleeding risk in patients receiving dual anti-platelet treatment and to detect the prevalence of patients with high bleeding risk, and to determine DAPT score which predicts benefit/risk ratio of continuing or discontinuing dual ant-iplatelet therapy after 12 months and to detect the prevalence of patients with high ischemic or hemorrhagic complication risk in centers included in this study.

Conditions

Anti-platelet Therapy

Outcome Measures

Primary Outcomes (1)

• ischemia

  ischemic events of patients on dual antiplatelet therapy

  3 months

Interventions

Demographical and Clinical Profile of Patients on Dual Antıplatelet Therapy OTHER

Demographical and Clinical Profile of Patients on Dual Antıplatelet Therapy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients that have acute coronary syndrome or percutaneous coronary intervention electively and with available admission heamoglobin, white blood cell and creatine clearance data and on dual antiplatelet therapy

You may qualify if:

• Patients that have acute coronary syndrome or percutaneous coronary intervention electively and with available admission heamoglobin, white blood cell and creatine clearance data and on dual antiplatelet therapy

You may not qualify if:

• Being under eighteen years old

Sponsors & Collaborators

• Cardiovascular Academy Society, Turkey: lead

Study Sites (1)

Balikesir University

Balıkesir, Turkey (Türkiye)

Location

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 27, 2018
• First Posted: July 26, 2018
• Study Start: March 1, 2018
• Primary Completion: November 1, 2018
• Study Completion: March 1, 2019
• Last Updated: May 7, 2019

Record last verified: 2019-05

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)